Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life
Submitted: 3 December 2019
Accepted: 15 April 2020
Published: 23 July 2020
Accepted: 15 April 2020
Abstract Views: 1347
PDF: 984
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- C. Contessa, R. Ramonda, A. Lo Nigro, V. Modesti, M. Lorenzin, M. Puato, M. Zanon, G. Balbi, A. Doria, L. Punzi, Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data , Reumatismo: Vol. 61 No. 4 (2009)
- C. Tani, M. Mosca, A. d'Ascanio, D. Versari, A. Virdis, L. Ghiadoni, S. Taddei, A. Salvetti, S. Bombardieri, Chronic inflammation and endothelial dysfunction: analysis of a cohort of patients with SLE and UCTD , Reumatismo: Vol. 58 No. 3 (2006)
- A. Tincani, C. Casu, S. Cartella, T. Ziglioli, R. Cattaneo, Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations , Reumatismo: Vol. 62 No. 1 (2010)
You may also start an advanced similarity search for this article.